Overview ATRi Transition Rollover Study Status: Active, not recruiting Trial end date: 2022-01-01 Target enrollment: Participant gender: Summary The main purpose of the study is to monitor the safety of participant receiving long-term treatment of M6620 as monotherapy or in combination with carboplatin and paclitaxel. Phase: Phase 1 Details Lead Sponsor: Merck KGaAMerck KGaA, Darmstadt, GermanyTreatments: CarboplatinPaclitaxel